CD8A and neoplasm: M2-like TAMs block CD8 T cell-mediated anti-tumor immune response either directly, through their expression of inhibitor ligands, such as the programmed death-ligand 1 (PD-L1), or indirectly, via the C-C motif chemokine ligand 22 (CCL-22)-mediated recruitment of regulatory T cells (Tregs).